Herbalife reported fourth quarter 2024 net sales of $1.2 billion, a slight decrease of 0.6% year-over-year, but an increase of 2.7% on a constant currency basis. Adjusted EBITDA of $150.0 million exceeded guidance, with the adjusted EBITDA margin up 340 basis points compared to Q4 2023. Diluted EPS was $1.74, and adjusted diluted EPS was $0.36.
Net sales for Q4 2024 were $1.2 billion, down 0.6% year-over-year, but up 2.7% on a constant currency basis, reaching the high end of guidance.
Adjusted EBITDA for Q4 2024 was $150.0 million, exceeding guidance, with the adjusted EBITDA margin increasing by 340 basis points compared to Q4 2023.
Diluted EPS for Q4 2024 was $1.74, and adjusted diluted EPS was $0.36.
The company reported three consecutive quarters of new distributor growth, with a 22% year-over-year increase in new distributors joining worldwide in Q4.
For Q1 2025, Herbalife expects net sales to decline by 5.5% to 1.5% year-over-year, but to be flat to up 4% on a constant currency basis. Adjusted EBITDA is projected to be between $140 million and $150 million, or $158 million to $168 million at constant currency. For the full year 2025, net sales are expected to be down 3% to up 3% year-over-year, or up 1% to 7% at constant currency. Adjusted EBITDA is projected to be between $600 million and $640 million, or $670 million to $710 million at constant currency.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance